Editas Medicine I…
USUSDEditas Medicine Inc (US:EDIT) — Biotechnology: Biological Products (No Diagnostic Substances). Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За Компанията
- Уебсайт
- editasmedicine.com
- Връзки с Инвеститорите
- ir.editasmedicine.com/investor-relations
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Централа
- Cambridge, United States
- Изпълнителен Директор
- Gilmore O'Neill
- Служители
- 87
- Основана
- 2013
- Акции в Обращение
- 153.58 млн към 2026-07-31
- Свободно Търгуеми Акции
- 115.49 млн
- Пазарна Капитализация
- 397.77 млн USD
- Инсайдери
- 0.18%
- Институционални Инвеститори
- 79.29%
- Отрасъл (SIC)
- Biological Products, (No Diagnostic Substances)
- ISIN
- US28106W1036
- LEI
- 5299000AON4Q9NT2JE42
- P/E
- загуба
- FCF
- −121 млн USD
- Дълг
- 55.7 млн USDнетни парични средства
- Печалби и FCF — за 12-те месеца до 30.06.2026 (последният доклад на компанията).
- NAV
Описание
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Най-Големи Притежатели
| Притежател | Дял | Акции | Дата на Доклада |
|---|---|---|---|
| TCG Crossover Management… | 7.23% | 11.11 млн | 2026-06-30 |
| Blackrock Inc. | 6.9% | 10.59 млн | 2026-06-30 |
| Commodore Capital Lp | 5.79% | 8.89 млн | 2026-06-30 |
| RA Capital Management, L… | 5.79% | 8.89 млн | 2026-06-30 |
| Adar1 Capital Management… | 5.79% | 8.89 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4% | 6.14 млн | 2026-06-30 |
| Paradigm Biocapital Advi… | 3.64% | 5.59 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 4.89 млн | 2026-06-30 |
| Opaleye Management Inc. | 2.51% | 3.86 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.34% | 3.6 млн | 2026-06-30 |
| Woodline Partners LP | 2.32% | 3.56 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.68% | 2.58 млн | 2026-07-31 |
| VANGUARD HORIZON FUNDS-V… | 1.32% | 2.03 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.72% | 1.1 млн | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.71% | 1.09 млн | 2026-07-31 |
| iShares Trust-iShares Bi… | 0.69% | 1.06 млн | 2026-08-31 |
| iShares Trust-iShares Ru… | 0.55% | 850 485 | 2026-08-31 |
| Fidelity Concord Street… | 0.34% | 522 584 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.33% | 505 306 | 2026-05-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.31% | 476 309 | 2026-05-31 |
| O NEILL GILMORE NEIL (Ch… | ≈0.16% | 243 189 | 2026-09-03 |
| MEI BAISONG (Officer) | ≈0.09% | 133 354 | 2024-12-03 |
| LUCERA ERICK J. (Chief F… | ≈0.07% | 112 720 | 2025-03-04 |
| BURKLY LINDA (Officer) | ≈0.04% | 61 660 | 2026-09-03 |
| PARISON AMY (Chief Finan… | ≈0.01% | 13 839 | 2026-09-03 |
